Mbot likely fda approval date

The likely FDA approval date for Microbot Medical's LIBERTY Endovascular Robotic System is the third quarter of 2025 (Q3 2025). This conclusion is based on the following points: 1. **FDA Review Timeline**: The FDA review for the LIBERTY System is anticipated to occur in Q3 2025, as stated by the company and analysts. 2. **Previous Milestones**: Microbot Medical has already submitted the 510(k) premarket notification in December 2024, which follows the successful completion of the pivotal human clinical trial. The company has been actively preparing for commercialization after FDA clearance, indicating a planned launch around the anticipated approval window. 3. **Recent Developments**: The company has strengthened its commercial capabilities by appointing Michael Lytle as head of Sales Operations & Analytics, bringing extensive experience in sales support and data analysis. This strategic move is indicative of Microbot Medical's readiness for the commercial launch. 4. **Market Expectations**: Analysts have set price targets for MBOT, suggesting potential growth following FDA approval. The company's engagement with strategic partners and the anticipation of significant market demand post-approval further support the expectation of a Q3 2025 approval. In summary, the combination of the FDA review timeline, previous milestones, recent developments, and market expectations strongly suggest that the likely FDA approval date for MBOT is Q3 2025.